220 related articles for article (PubMed ID: 31336860)
21. Plk1 regulates liver tumor cell death by phosphorylation of TAp63.
Komatsu S; Takenobu H; Ozaki T; Ando K; Koida N; Suenaga Y; Ichikawa T; Hishiki T; Chiba T; Iwama A; Yoshida H; Ohnuma N; Nakagawara A; Kamijo T
Oncogene; 2009 Oct; 28(41):3631-41. PubMed ID: 19668228
[TBL] [Abstract][Full Text] [Related]
22. HOXB4 knockdown enhances the cytotoxic effect of paclitaxel and cisplatin by downregulating ABC transporters in ovarian cancer cells.
Li Y; Sun J; Gao S; Hu H; Xie P
Gene; 2018 Jul; 663():9-16. PubMed ID: 29660518
[TBL] [Abstract][Full Text] [Related]
23. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
[TBL] [Abstract][Full Text] [Related]
24. Grifolin, a potent antitumour natural product upregulates death-associated protein kinase 1 DAPK1 via p53 in nasopharyngeal carcinoma cells.
Luo XJ; Li LL; Deng QP; Yu XF; Yang LF; Luo FJ; Xiao LB; Chen XY; Ye M; Liu JK; Cao Y
Eur J Cancer; 2011 Jan; 47(2):316-25. PubMed ID: 20943371
[TBL] [Abstract][Full Text] [Related]
25. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
26. WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response.
Janczar S; Nautiyal J; Xiao Y; Curry E; Sun M; Zanini E; Paige AJ; Gabra H
Cell Death Dis; 2017 Jul; 8(7):e2955. PubMed ID: 28749468
[TBL] [Abstract][Full Text] [Related]
27. Death-associated protein kinase 1 promotes growth of p53-mutant cancers.
Zhao J; Zhao D; Poage GM; Mazumdar A; Zhang Y; Hill JL; Hartman ZC; Savage MI; Mills GB; Brown PH
J Clin Invest; 2015 Jul; 125(7):2707-20. PubMed ID: 26075823
[TBL] [Abstract][Full Text] [Related]
28. Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression.
Mao K; Liu F; Liu X; Khuri FR; Marcus AI; Li M; Zhou W
Lung Cancer; 2015 May; 88(2):131-8. PubMed ID: 25769882
[TBL] [Abstract][Full Text] [Related]
29. CRM197 reverses paclitaxel resistance by inhibiting the NAC-1/Gadd45 pathway in paclitaxel-resistant ovarian cancer cells.
Tang XH; Li H; Zheng XS; Lu MS; An Y; Zhang XL
Cancer Med; 2019 Oct; 8(14):6426-6436. PubMed ID: 31490008
[TBL] [Abstract][Full Text] [Related]
30. TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells.
Sun NK; Huang SL; Chang TC; Chao CC
J Cell Physiol; 2018 Mar; 233(3):2489-2501. PubMed ID: 28771725
[TBL] [Abstract][Full Text] [Related]
31. Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein.
Stordal B; Hamon M; McEneaney V; Roche S; Gillet JP; O'Leary JJ; Gottesman M; Clynes M
PLoS One; 2012; 7(7):e40717. PubMed ID: 22792399
[TBL] [Abstract][Full Text] [Related]
32. TXNDC17 promotes paclitaxel resistance via inducing autophagy in ovarian cancer.
Zhang SF; Wang XY; Fu ZQ; Peng QH; Zhang JY; Ye F; Fu YF; Zhou CY; Lu WG; Cheng XD; Xie X
Autophagy; 2015; 11(2):225-38. PubMed ID: 25607466
[TBL] [Abstract][Full Text] [Related]
33. miR-129 targets CDK1 and iASPP to modulate Burkitt lymphoma cell proliferation in a TAp63-dependent manner.
Zou H; Zou R; Chen K; Zhu C; Tian X; You Y; He X
J Cell Biochem; 2018 Nov; 119(11):9217-9228. PubMed ID: 30105797
[TBL] [Abstract][Full Text] [Related]
34. WWOX promotes apoptosis and inhibits autophagy in paclitaxel‑treated ovarian carcinoma cells.
Zhao Y; Wang W; Pan W; Yu Y; Huang W; Gao J; Zhang Y; Zhang S
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33300063
[TBL] [Abstract][Full Text] [Related]
35. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts.
Washington MN; Suh G; Orozco AF; Sutton MN; Yang H; Wang Y; Mao W; Millward S; Ornelas A; Atkinson N; Liao W; Bast RC; Lu Z
Cell Death Dis; 2015 Aug; 6(8):e1836. PubMed ID: 26247722
[TBL] [Abstract][Full Text] [Related]
36. Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
Xu J; Wu J; Fu C; Teng F; Liu S; Dai C; Shen R; Jia X
J Cell Physiol; 2018 Jun; 233(6):5034-5043. PubMed ID: 29219179
[TBL] [Abstract][Full Text] [Related]
37. MiR-191 inhibits TNF-α induced apoptosis of ovarian endometriosis and endometrioid carcinoma cells by targeting DAPK1.
Tian X; Xu L; Wang P
Int J Clin Exp Pathol; 2015; 8(5):4933-42. PubMed ID: 26191186
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis.
Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092
[TBL] [Abstract][Full Text] [Related]
40. UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis.
Wang J; Ye C; Liu J; Hu Y
Biochem Biophys Res Commun; 2018 Jul; 501(4):1034-1040. PubMed ID: 29777711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
